Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Psyence Biomedical ( (PBM) ) just unveiled an update.
On February 20, 2026, Psyence Biomedical announced that Psyence Labs exercised a previously agreed put option, triggering a US$5 million share‑for‑share equity investment structured as a non‑cash exchange. Psyence BioMed will receive 2,900 PsyLabs shares valued at US$1,724 each, while issuing 1,146,159 new common shares, based on a 30‑day VWAP of US$4.36, with closing targeted around February 25, 2026.
The deal will leave PsyLabs holding about 49.98% of Psyence BioMed’s outstanding shares, significantly diluting existing shareholders but deepening vertical integration and securing long‑term access to pharmaceutical‑grade psychedelic manufacturing. Given overlapping management ties, the transaction was treated as a related‑party deal, reviewed and approved by an independent special committee that relied on third‑party valuation and legal advice to confirm fairness for non‑conflicted shareholders.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a Nasdaq-listed, multi‑asset biopharmaceutical company developing nature‑derived, non‑synthetic psilocybin and ibogaine‑based psychedelic medicines for unmet mental health needs. Through a vertically integrated model and partnerships such as Psyence Labs Ltd., it focuses on securing pharmaceutical‑grade psychedelic supply for clinical and future commercialization programs.
Average Trading Volume: 300,209
Technical Sentiment Signal: Sell
Current Market Cap: $2.71M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.